This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Covx Technologies Ireland Limited. Active years: 2015.
Company Filing History:
Years Active: 2015
Title: Nicholas Gary Luksha: Innovator in Anti-Diabetic Compounds
Introduction
Nicholas Gary Luksha is a notable inventor based in North Andover, MA (US). He has made significant contributions to the field of diabetes treatment through his innovative research and development of anti-diabetic compounds. His work has the potential to impact the lives of many individuals suffering from diabetes and related conditions.
Latest Patents
Nicholas Gary Luksha holds a patent for a composition designed to prevent or treat diabetes. The patent, titled "Anti-diabetic compounds," presents a unique formula: [FGF21-1Linker]-[Ab]-[2-Linker-Ex4]. This composition includes an FGF21 homologue, an Exendin4 homologue, and an aldolase catalytic antibody or its antigen-binding portion. The invention outlines various uses of these compounds, emphasizing their potential in diabetes management.
Career Highlights
Throughout his career, Luksha has worked with prominent companies in the biotechnology sector. He has been associated with Covx Technologies Ireland Limited and Wyeth, where he contributed to various research initiatives. His experience in these organizations has helped him refine his skills and expand his knowledge in the field of medical innovations.
Collaborations
Nicholas Gary Luksha has collaborated with several professionals in his field. Notable coworkers include Palani Balu and Haim Moskowitz, who have worked alongside him on various projects related to diabetes treatment and research.
Conclusion
Nicholas Gary Luksha is a dedicated inventor whose work in anti-diabetic compounds showcases his commitment to improving healthcare solutions. His innovative approach and collaboration with industry professionals highlight the importance of research in combating diabetes.